Emerging markets are a big opportunity for pharma companies. But from the R&D productivity standpoint, these markets create new challenges in genomic complexity. So, in research and clinic development process, trials need to be more inclusive taking into context the wider population that the companies will have to deal with..
For more details, download White Paper here:
The Higher Outcomes Lower Costs
Only registered and logged in users can download this file.